Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scienture HoldingsSCNX -4.57%47 Return-on-Tangible-Asset is -116.57% as of Mar. 2026. GuruFocus rates SCNX with a GF Score™ of 47/100 and a GF Value™ of $0.35 (Fairly Valued). The stock has 6 warning signs investors should review. Among 679 Healthcare Providers & Services companies, Scienture Holdings ranks worse than 97.79% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Scienture Holdings's annualizedNet Income for the quarter that ended in Mar. 2026 was $-13.61 Mil. Scienture Holdings's average total tangible assets for the quarter that ended in Mar. 2026 was $11.67 Mil. Therefore, Scienture Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -116.57%.
The historical rank and industry rank for Scienture Holdings's Return-on-Tangible-Asset or its related term are showing as below:
SCNX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -459.76 Med: -51.49 Max: 92.44
Current: -459.76
During the past 13 years, Scienture Holdings's highest Return-on-Tangible-Asset was 92.44%. The lowest was -459.76%. And the median was -51.49%.
SCNX's Return-on-Tangible-Asset is ranked worse than 97.79% of 679
companies
in the Healthcare Providers & Services industry
Industry Median: 2.51
vs SCNX: -459.76
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Scienture Holdings Return-on-Tangible-Asset Related Terms
Scienture Holdings Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Scienture Holdings's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCNX vs WGRX, HEWA, BLMH: Return-on-Tangible-Asset Comparison
For the Pharmaceutical Retailers subindustry, Scienture Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scienture Holdings Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Scienture Holdings's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Scienture Holdings's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -116.57% mean?
Scienture Holdings (SCNX) has a Return-on-Tangible-Asset of -116.57% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Scienture Holdings and its competitors. According to the industry distribution chart, Scienture Holdings ranks #664 out of 679 companies in the Healthcare Providers & Services industry, placing it in the top 97.8%.
Is Scienture Holdings' Return-on-Tangible-Asset too high?
Scienture Holdings' current Return-on-Tangible-Asset is -116.57%. Based on the distribution chart, Scienture Holdings ranks #664 out of 679 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Scienture Holdings has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scienture Holdings' Return-on-Tangible-Asset compare to WGRX and HEWA?
According to the Healthcare Providers & Services industry distribution chart, Scienture Holdings ranks #664 out of 679 companies for Return-on-Tangible-Asset. This places Scienture Holdings in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.51, based on 679 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Scienture Holdings and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scienture Holdings's current Return-on-Tangible-Asset is -116.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scienture Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scienture Holdings (SCNX) is currently considered Fairly Valued. The stock's GF Value™ is $0.35, compared to a current price of $0.37 — trading 7% above its estimated fair value. The current Return-on-Tangible-Asset is -116.57%. Scienture Holdings' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Scienture Holdings (SCNX), the current Return-on-Tangible-Asset is -116.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scienture Holdings (SCNX) Overvalued in 2026?
Based on GuruFocus' analysis, Scienture Holdings stock appears to be overvalued.
The current stock price of $0.37 is trading 7% above its estimated GF Value™ of $0.35.
GuruFocus considers Scienture Holdings to be Fairly Valued.
Key valuation signals for SCNX:
Return-on-Tangible-Asset: -116.57%
GF Value™: $0.35 vs. price of $0.37 (7% above fair value)
No single metric tells the full story. See the SCNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
47GF Score
Get the complete analysis for SCNX
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNX has been successfully added to your 
